Search research articles
Contact Us
Filters
Showing results (11-20 of 39) with videos related to
Page
of 4
Sort By:
Journal of the National Cancer Institute
|
May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
Holger Schulz, Julia F Bohlius, Sven Trelle, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2022
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
Carla Casulo, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Cancer Research and Clinical Oncology
|
July 6, 2019
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial
Laura Budau, Christian Wilhelm, Roland Moll, et al.
American Journal of Hematology
|
August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy
Farheen Mir, Federico Mattiello, Andrew Grigg, et al.
Academic Radiology
|
March 19, 2015
Is "prepectoral edema" a morphologic sign for malignant breast tumors?
Clemens G Kaiser, Michael Herold, Pascal A T Baltzer, et al.
Hemasphere
|
March 2, 2022
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Michael Herold, Eva Hoster, Ann Janssens, et al.
Leukemia & Lymphoma
|
June 30, 2004
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)
Michael Koenigsmann, Wolfgang Knauf, Michael Herold, et al.
Blood
|
October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Holger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Leukemia & Lymphoma
|
May 10, 2002
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study
Luisa Mantovani, Dirk Hasenclever, Rainer Krahl, et al.
Archives of Toxicology
|
September 4, 2023
Application of high throughput in vitro metabolomics for hepatotoxicity mode of action characterization and mechanistic-anchored point of departure derivation: a case study with nitrofurantoin
Sabina Ramirez-Hincapie, Barbara Birk, Philipp Ternes, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 39) with videos related to
Sort By:
Page
of 4
Journal of the National Cancer Institute
|
May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
Holger Schulz, Julia F Bohlius, Sven Trelle, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2022
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
Carla Casulo, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Cancer Research and Clinical Oncology
|
July 6, 2019
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial
Laura Budau, Christian Wilhelm, Roland Moll, et al.
American Journal of Hematology
|
August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy
Farheen Mir, Federico Mattiello, Andrew Grigg, et al.
Academic Radiology
|
March 19, 2015
Is "prepectoral edema" a morphologic sign for malignant breast tumors?
Clemens G Kaiser, Michael Herold, Pascal A T Baltzer, et al.
Hemasphere
|
March 2, 2022
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Michael Herold, Eva Hoster, Ann Janssens, et al.
Leukemia & Lymphoma
|
June 30, 2004
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)
Michael Koenigsmann, Wolfgang Knauf, Michael Herold, et al.
Blood
|
October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Holger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Leukemia & Lymphoma
|
May 10, 2002
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study
Luisa Mantovani, Dirk Hasenclever, Rainer Krahl, et al.
Archives of Toxicology
|
September 4, 2023
Application of high throughput in vitro metabolomics for hepatotoxicity mode of action characterization and mechanistic-anchored point of departure derivation: a case study with nitrofurantoin
Sabina Ramirez-Hincapie, Barbara Birk, Philipp Ternes, et al.
Page
of 4